Researchers evaluated a blood test’s ability to predict recurrence in patients with stage 3 melanoma.
Melanoma News
Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma
Stergios J. Moschos, MD, an associate professor of medicine in the Department of Medicine in the Division of Oncology at the University of North Carolina (UNC) Chapel Hill School of Medicine, UNC Health, emphasized the importance of appropriately administering bridging therapy to patients who are slated to receive the adoptive T-cell therapy lifileucel (Amtagvi).
Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition
Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.
Comparing Melanoma Immunotherapy Outcomes in Key Clinical Trials
During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.
This article is part 1 of a 2-part series from a Case-Based Roundtable event.